Bisoprolol: the pathway in the body
This page shows the biochemical pathway of the active substance Bisoprolol: where it arrives in the body, where it acts and which steps are affected by that. Every statement has a source. The page describes general textbook knowledge and says nothing about any individual person.
In brief
Bisoprolol is a beta blocker. It settles into the binding pocket of the β₁ receptor, where noradrenaline otherwise sits. Both share the same pocket: while bisoprolol sits in it, the chain up to cAMP starts more slowly.
What this is about
The β₁ receptor sits not only on the heart. Wherever it sits, the same chain runs:
- Noradrenaline binds at the β₁ receptor. The coupled Gs protein switches on adenylyl cyclase, and the messenger cAMP arises out of ATP.
- At the sinus node cAMP binds directly to the HCN channels. They set the beat of the heart.
- In the pineal gland cAMP switches on the regulator CREB by way of protein kinase A. The amount of the enzyme AANAT then grows during the night.
- AANAT makes N-acetylserotonin out of serotonin, and the enzyme ASMT makes melatonin out of that. The AANAT step is the slowest of this chain.
Bisoprolol occupies the binding pocket of the β₁ receptor. What is occupied is the binding pocket; the receptor is not altered: the same chain starts up more slowly in both places, and noradrenaline still competes for the same site. For beta blockers a smaller nightly melatonin release is described: in one trial in healthy volunteers, only the beta-blocking forms of propranolol and atenolol lowered the melatonin breakdown product excreted at night. In a later comparison of three substances, the nightly melatonin release came out smaller on bisoprolol, and not on carvedilol or nebivolol.
What this means in an individual case depends on many things and belongs in a conversation with a doctor or health practitioner.
Swipe the graphic sideways
The pathway step by step
- Bisoprolol → Uptake in the gut From the small bowel the substance passes into the blood. The label puts the absorbed share at roughly four fifths of the swallowed amount and notes that food does not change it. Source 10
- Uptake in the gut → Travelling in the blood In the blood only a small part is bound to protein; the rest is free and reaches the tissues. β₁ receptors sit among other places on the heart and on the pineal gland. Source 10, 4
- Travelling in the blood → Elimination About half leaves the body unchanged in the urine, the other half is converted in the liver into inactive breakdown products. The enzyme CYP2D6 has no part in this. Source 10
- β₁ at the sinus node → cAMP and HCN channels adenylyl cyclase · Gs protein, Mg-ATP Adenylyl cyclase makes the messenger cAMP out of ATP. cAMP binds directly to the HCN channels of the sinus node; the more of it is bound, the sooner the next beat follows. Source 3
- β₁ at the pineal gland → cAMP in the pinealocyte adenylyl cyclase · Gs protein, Mg-ATP Here too the Gs protein switches on adenylyl cyclase, and cAMP arises. The α₁ receptors act alongside it but do not carry the rise on their own. Source 4, 1
- cAMP in the pinealocyte → AANAT PKA and CREB cAMP switches on protein kinase A, and this in turn the regulator CREB. The amount of the enzyme AANAT then grows during the night. Because of this gait it carries the byname timezyme. Source 4, 5
- AANAT → N-acetylserotonin AANAT · acetyl-CoA AANAT hangs an acetyl group from acetyl-CoA onto serotonin. How much AANAT is present at that moment sets how much N-acetylserotonin arises in the night. Source 5
- N-acetylserotonin → Melatonin ASMT · SAM The enzyme ASMT transfers a methyl group from SAM onto N-acetylserotonin. Melatonin leaves the pineal gland and spreads through the body with the blood. Source 4, 5
- Tryptophan → Serotonin TPH, then AADC · iron and BH4, vit. B6 (PLP) Two enzymes lead there: tryptophan hydroxylase with iron and BH4 hangs on an OH group, then AADC with pyridoxal phosphate removes a carboxyl group. Source 8, 9
What depends on the β₁ receptor
- Noradrenaline — Binds at the β₁ receptor; bisoprolol occupies the same pocket and sits there in its place Source 1, 10
- Melatonin — The pineal gland governs AANAT through β₁ receptors; under beta blockers a smaller nightly release is described Source 4, 6, 7
What takes part in these steps
- Tryptophan — Amino acid at the start of the chain: serotonin arises from it, and from that melatonin in the pineal gland Source 4
- Serotonin — Starting substance of AANAT: N-acetylserotonin arises from serotonin Source 5
- Vitamin B6 — As pyridoxal phosphate the cofactor of AADC, which makes serotonin out of 5-HTP Source 9
- Acetyl-CoA — Supplies AANAT with the acetyl group for N-acetylserotonin Source 5
- SAM (from methionine) — Methyl group donor of ASMT, which converts N-acetylserotonin into melatonin Source 4, 5
- ATP — Adenylyl cyclase makes cAMP out of it, the messenger behind the β₁ receptor Source 1, 3
What the prescribing information states
Two placebo-controlled trials in the United States. Shown here is the subgroup within the usual amount range: 273 adults on bisoprolol and 132 on placebo. Listed are the events that occurred in at least 1 of 100 participants of the bisoprolol group — whether or not a connection with the substance was assumed. The figures apply to these trials.
How to read the table: what matters is the comparison within the row, not the single figure. For headache, dizziness, cough and sleeplessness the figure on placebo is higher than on bisoprolol. The two columns move clearly apart only for fatigue. There is no third column with another medicine here — this prescribing information compares against placebo alone.
| Bisoprolol (273) | Placebo (132) | |
|---|---|---|
| Headache | 8.8% | 11.4% |
| Fatigue | 6.6% | 1.5% |
| Upper respiratory infection | 4.8% | 3.8% |
| Fluid retention | 3.7% | 3.8% |
| Dizziness | 2.9% | 3.8% |
| Runny nose | 2.9% | 3.0% |
| Diarrhoea | 2.6% | 1.5% |
| Cough | 2.6% | 4.5% |
| Joint pain | 2.2% | 2.3% |
| Sore throat | 2.2% | 2.3% |
| Sinusitis | 2.2% | 1.5% |
| Nausea | 1.5% | 1.5% |
| Sleeplessness | 1.5% | 2.3% |
| Vomiting | 1.1% | 0% |
| Numbness of the skin | 1.1% | 0.8% |
| Shortness of breath | 1.1% | 0.8% |
| Chest pain | 1.1% | 0.8% |
In the same trials, 3.3 of 100 participants on bisoprolol stopped because of an event, and 6.8 of 100 on placebo. Across all worldwide trials and the reports after approval, the prescribing information carries a long list of further events, among them sleep disturbances and vivid dreams. For the reports after approval it notes that neither a frequency nor a causal relationship can be derived from them; they are therefore not listed here.
Sources
- Motiejunaite J, Amar L, Vidal-Petiot E. Adrenergic receptors and cardiovascular effects of catecholamines. Ann Endocrinol (Paris) 2021 · PubMed 32473788
- Taddei S, Tsabedze N, Tan RS. β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Curr Med Res Opin 2024 · PubMed 38597065
- DiFrancesco D. The funny current: cellular basis for the control of heart rate. Drugs 2007 · PubMed 17999560
- Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003 · PubMed 12773631
- Klein DC. Arylalkylamine N-acetyltransferase: "the Timezyme". J Biol Chem 2007 · PubMed 17164235
- Stoschitzky K, Sakotnik A, Lercher P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999 · PubMed 10335905
- Stoschitzky K, Stoschitzky G, Brussee H et al. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006 · PubMed 16679760
- Roberts KM, Fitzpatrick PF. Mechanisms of tryptophan and tyrosine hydroxylase. IUBMB Life 2013 · PubMed 23441081
- Paiardini A, Giardina G, Rossignoli G et al. New Insights Emerging from Recent Investigations on Human Group II Pyridoxal 5'-Phosphate Decarboxylases. Curr Med Chem 2017 · PubMed 27881066
- US prescribing information (United States): Bisoprolol Fumarate Tablets, USP, DailyMed, version of 21 Apr 2026, sections DESCRIPTION and CLINICAL PHARMACOLOGY (Pharmacokinetics and Metabolism, Pharmacodynamics) · Prescribing information
- US prescribing information (United States): Bisoprolol Fumarate Tablets, USP, DailyMed, version of 21 Apr 2026, section ADVERSE REACTIONS · Prescribing information
As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice
Privacy policy
All biomarkers